East Asian–Specific Common Variant in TNNI3 Predisposes to Hypertrophic Cardiomyopathy
Guixin Wu,Liwen Liu,Zhengyang Zhou,Jie Liu,Bo Wang,Jieyun Ruan,Qianli Yang,Mohammed Kanchwala,Peng Dai,Channa Zhang,Dong Wang,Lianming Kang,Shuiyun Wang,Hui Ren,Yubao Zou,Chao Xing,Lingyun Song,Jizheng Wang
DOI: https://doi.org/10.1161/circulationaha.120.050384
IF: 37.8
2020-01-01
Circulation
Abstract:HomeCirculationVol. 142, No. 21East Asian–Specific Common Variant in TNNI3 Predisposes to Hypertrophic Cardiomyopathy Free AccessLetterPDF/EPUBAboutView PDFView EPUBSections ToolsAdd to favoritesDownload citationsTrack citationsPermissions ShareShare onFacebookTwitterLinked InMendeleyRedditDiggEmail Jump toFree AccessLetterPDF/EPUBEast Asian–Specific Common Variant in TNNI3 Predisposes to Hypertrophic Cardiomyopathy Guixin Wu, MD Liwen Liu, MD Zhengyang Zhou, PhD Jie Liu, MD Bo Wang, MS Jieyun Ruan, MD Qianli Yang, MS Mohammed Kanchwala, MS Penggao Dai, PhD Channa Zhang, BS Dong Wang, MD Lianming Kang, MD Shuiyun Wang, MD Rutai Hui, MD, PhD Yubao Zou, MD Chao Xing, PhD Lei Song, MD, PhD Jizheng WangPhD Guixin WuGuixin Wu State Key Laboratory of Cardiovascular Disease(G.W., J.L., J.R., C.Z., R.H., Y.Z., L.S., J.W.), Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing. Cardiomyopathy Ward (G.W., J.L., J.R., D.W., L.K., L.S.), Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing. , Liwen LiuLiwen Liu Department of Ultrasound, Xijing Hospital, Fourth Military Medical University, Xi'an, Shaanxi, China (L.L., B.W., Q.Y.). , Zhengyang ZhouZhengyang Zhou Department of Biostatistics and Epidemiology, School of Public Health, University of North Texas Health Science Center, Fort Worth (Z.Z.). , Jie LiuJie Liu https://orcid.org/0000-0001-7627-2836 State Key Laboratory of Cardiovascular Disease(G.W., J.L., J.R., C.Z., R.H., Y.Z., L.S., J.W.), Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing. Cardiomyopathy Ward (G.W., J.L., J.R., D.W., L.K., L.S.), Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing. , Bo WangBo Wang Department of Ultrasound, Xijing Hospital, Fourth Military Medical University, Xi'an, Shaanxi, China (L.L., B.W., Q.Y.). , Jieyun RuanJieyun Ruan State Key Laboratory of Cardiovascular Disease(G.W., J.L., J.R., C.Z., R.H., Y.Z., L.S., J.W.), Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing. Cardiomyopathy Ward (G.W., J.L., J.R., D.W., L.K., L.S.), Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing. , Qianli YangQianli Yang Department of Ultrasound, Xijing Hospital, Fourth Military Medical University, Xi'an, Shaanxi, China (L.L., B.W., Q.Y.). , Mohammed KanchwalaMohammed Kanchwala https://orcid.org/0000-0001-6035-2970 Eugene McDermott Center for Human Growth and Development (M.K., C.X.), University of Texas Southwestern Medical Center, Dallas. , Penggao DaiPenggao Dai National Engineering Research Center for Miniaturized Detection Systems, College of Life Science, Northwest University, Xi'an, Shaanxi, China (P.D.). , Channa ZhangChanna Zhang State Key Laboratory of Cardiovascular Disease(G.W., J.L., J.R., C.Z., R.H., Y.Z., L.S., J.W.), Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing. , Dong WangDong Wang Cardiomyopathy Ward (G.W., J.L., J.R., D.W., L.K., L.S.), Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing. , Lianming KangLianming Kang Cardiomyopathy Ward (G.W., J.L., J.R., D.W., L.K., L.S.), Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing. , Shuiyun WangShuiyun Wang Department of Cardiac Surgery (S.W.), Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing. , Rutai HuiRutai Hui State Key Laboratory of Cardiovascular Disease(G.W., J.L., J.R., C.Z., R.H., Y.Z., L.S., J.W.), Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing. , Yubao ZouYubao Zou State Key Laboratory of Cardiovascular Disease(G.W., J.L., J.R., C.Z., R.H., Y.Z., L.S., J.W.), Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing. , Chao XingChao Xing Chao Xing, PhD, McDermott Center for Human Growth and Development, UT Southwestern Medical Center, 5323 Harry Hines Blvd, Dallas, TX 75390-8591. Email E-mail Address: [email protected] https://orcid.org/0000-0002-1838-0502 Eugene McDermott Center for Human Growth and Development (M.K., C.X.), University of Texas Southwestern Medical Center, Dallas. Department of Bioinformatics (C.X.), University of Texas Southwestern Medical Center, Dallas. Department of Population and Data Sciences (C.X.), University of Texas Southwestern Medical Center, Dallas. , Lei SongLei Song Lei Song, MD, PhD, Cardiomyopathy Ward, Fuwai Hospital, National Center for Cardiovascular Disease, 167, Beilishilu, Xicheng District, 100037 Beijing, China; Email E-mail Address: [email protected] State Key Laboratory of Cardiovascular Disease(G.W., J.L., J.R., C.Z., R.H., Y.Z., L.S., J.W.), Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing. Cardiomyopathy Ward (G.W., J.L., J.R., D.W., L.K., L.S.), Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing. National Clinical Research Center of Cardiovascular Diseases (L.S.), Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing. , Jizheng WangJizheng Wang Jizheng Wang, PhD, State Key Laboratory of Cardiovascular Disease, Cardiomyopathy Ward, Fuwai Hospital, National Center for Cardiovascular Disease, 167, Beilishilu, Xicheng District, 100037 Beijing, China; Email E-mail Address: [email protected] https://orcid.org/0000-0002-2961-524X State Key Laboratory of Cardiovascular Disease(G.W., J.L., J.R., C.Z., R.H., Y.Z., L.S., J.W.), Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing. Originally published20 Oct 2020https://doi.org/10.1161/CIRCULATIONAHA.120.050384Circulation. 2020;142:2086–2089Hypertrophic cardiomyopathy (HCM) is the most common inherited cardiac disorder characterized by unexplained left ventricular hypertrophy.1 Although considered as a dominant Mendelian disease mainly caused by rare pathogenic variants in sarcomere genes, the genetic underpinnings of nearly half of patients remain unsolved.2 Increasing evidence implies that HCM has a more complex genetic architecture.3 We identified an East Asian–specific common missense variant in TNNI3 (rs3729712) associated with HCM in an exome-wide case–control association study of Chinese origin and replicated the finding in 3 independent studies (P=5.80×10–22).Both the discovery study (986 cases and 761 controls) and the Beijing replication study4 (529 cases and 307 controls) were from Fuwai Hospital, Chinese Academy of Medical Sciences, Beijing. The other 2 replication studies, Xi'an-1 (646 cases and 468 controls) and Xi'an-2 (670 cases and 577 controls), were from Xijing Hospital of Fourth Military Medical University, Xi'an, Shaanxi. HCM was diagnosed by the presence of a maximal ventricular wall thickness ≥15 mm, or ≥13 mm in individuals with a family history of HCM, in the absence of any abnormal loading conditions capable of producing such a magnitude of hypertrophy. HCM was excluded in all the controls by a lack of primary left ventricular hypertrophy on echocardiography. The study protocols were approved by the ethics committees of both hospitals. Written informed consent was obtained from each participant. Detailed methods and results are available from the corresponding author on reasonable request and in accordance with the data sharing agreement.The discovery study samples underwent whole exome sequencing. Both single-variant association screen for common variants and gene-based association screen for rare variants were performed. As expected, rare variants in MYH7 and MYBPC3, the 2 most common causal genes of HCM, were greatly enriched in patients (Figure A). There was no novel gene attaining genome-wide significance. The single-variant association screen identified a common variant rs3729712 in TNNI3 (NC_000019:g.55667616G>A; NM_000363:c.235C>T; NP_000354:p.Arg79Cys) associated with HCM (Figure B). The minor allele frequency (MAF) of this variant was significantly higher in patients (0.055) than in controls (0.016), with the odds ratio (95% CI) per risk allele estimated to be 3.31 (2.12, 5.15; P=1.28×10–7). The association was confirmed in each of the 3 replication studies, among which the Beijing replication samples and Xi'an-1 cases were genotyped by a panel sequencing of cardiomyopathy candidate genes, and the Xi'an-1 controls and Xi'an-2 samples by Sanger sequencing. The fixed-effects meta-analysis of all 4 studies estimated the odds ratio (95% CI) per risk allele to be 4.62 (3.39–6.30; Figure C).Download figureDownload PowerPointFigure. Association of TNNI3 rs3729712 with hypertrophic cardiomyopathy (HCM). A, Quantile–quantile plot of the observed P values vs the expected P values for the gene-based rare variants sequence kernel association test in the discovery study. The rare variants include missense, nonsense, splicing, and frameshift variants with Genomic Evolutionary Rate Profiling score ≥2 and minor allele frequency <0.01 in the whole study. There were 16 568 genes containing the qualified rare variants. The dashed line represents the genome-wide significance threshold by Bonferroni correction (0.05/16 568=3.02×10–6). Two genes, MYH7 (P=5.55×10–31) and MYBPC3 (P=3.43×10–9), attained genome-wide significance. B, Quantile–quantile plot of the observed P values vs the expected P values for the single-variant association test by logistic regression in the discovery study. There were 203 455 common variants with minor allele frequency ≥0.01 in the whole study. The dashed line represents the genome-wide significance threshold by Bonferroni correction (0.05/203 455=2.46×10–7). One variant, rs3729712 in TNNI3 (P=1.28×10–7), attained genome-wide significance. C, Fixed-effects meta-analysis of the regression coefficients weighting by the inverse of the variance. The odds ratio (OR) was estimated as the odds of being affected on an increase of 1 copy of the risk allele rs3729712[A] by fitting a logistic regression model. Patients with HCM were classified into SARC+ (pathogenic or likely pathogenic variant identified in a sarcomere gene) and SARC– (no potentially pathogenic variant identified in a sarcomere gene) groups by the presence of any variant of pathogenic, likely pathogenic, or unknown significance in the 8 sarcomere genes (MYH7, MYBPC3, TNNT2, TNNI3, MYL2, MYL3, TPM1, and ACTC1) in the discovery study (495 vs 491), Beijing replication study (226 vs 303), and Xi'an-1 study (342 vs 304). Patients in Xi'an-2 could not be categorized because only rs3729712 was genotyped by Sanger sequencing. The minor allele frequencies (cases vs controls) of rs3729712 in the 4 studies were 0.055 vs 0.016, 0.035 vs 0.0065, 0.055 vs 0.0096, and 0.070 vs 0.0087, respectively; the minor allele frequencies (SARC+ vs SARC–) of rs3729712 in the cases were 0.032 vs 0.076 in the discovery study, 0.017 vs 0.048 in the Beijing replication study, and 0.037 vs 0.076 in the Xi'an-1 study. D, Expression levels of TNNI3 in 21 rs3729712[A] carriers (R79C+) and 21 noncarriers (R79C–). We performed RNA sequencing on myocardial tissue of 42 patients with HCM who underwent Morrow septal myectomy. Expression levels were quantified by transcripts per million (TPM). The error bar indicates 1 SD from the mean. There is no statistical difference between the 2 groups (P>0.05). E, Heatmap of ψ5 values for 5′ intron donor sites identified at TNNI3. ψ (percent-spliced-in) is defined as the proportion of reads supporting a specific splicing event relative to the combined number of reads. Each row corresponds to a patient. Column names indicate the hg38 coordinates of introns tested. There are 9 junctions after filtering for mean counts ≥10 across all samples. Note that junctions chr19:55157134−55157250 and chr19:55157129−55157561 do not belong to the canonical transcript NM_000363. Similar results were obtained for ψ3 but the heatmap was not shown. Neither aberrant splicing event nor different splicing pattern was detected in the R79C– patients compared with the R79C+ patients.We further classified patients into SARC+ and SARC– groups by the presence or absence of any variant of pathogenic, likely pathogenic, or unknown significance in the 8 sarcomere genes (MYH7, MYBPC3, TNNT2, TNNI3, MYL2, MYL3, TPM1, and ACTC1) using the American College of Medical Genetics and Genomics/Association for Molecular Pathology guidelines,5 and compared the distribution of rs3729712 between groups (Figure C). Compared with controls, the odds ratios (95% CIs) of rs3729712[A] were 5.27 (3.65–7.61) and 2.64 (1.76–3.96) in the SARC– and SARC+ groups, respectively. The rs3729712[A] allele was more frequent in the SARC– group than in the SARC+ group (MAF 0.068 and 0.030, respectively; P=4.63×10–7). The results indicate that SARC– patients likely have a different genetic architecture than do SARC+ patients.The association signal is unlikely attributable to other pathogenic variants in linkage disequilibrium with rs3729712. There were only 3 of 98 cases with rs3729712[A] having a TNNI3 nonsynonymous variant in the discovery study, 0 of 33 in the Beijing replication study, and 1 of 65 in Xi'an-1, which excluded the possibility of rs3729712[A] in linkage disequilibrium with another exonic pathogenic variant. RNA sequencing analysis showed neither altered expression levels (Figure D) nor aberrant splicing events in the myocardium of rs3729712[A] carriers (Figure E), which largely excluded the possibility of rs3729712[A] in linkage disequilibrium with a nonexonic pathogenic variant. Furthermore, we followed up 42 families of probands carrying rs3729712[A], and assessed 69 family members with heterozygous rs3729712[A] but without a sarcomere pathogenic variant, and none of them presented left ventricular hypertrophy.The TNNI3 rs3729712[A] allele appears to be specific to East Asians. In the 1000 Genomes Project and the Asian Admixed Genomes Consortium databases, the variant was only detected in East Asians with MAF of 0.0060 and 0.0092, respectively. In the gnomAD database, MAF was 0.0062 in East Asians, 0.00016 in South Asians, 0.000029 in Latinos, and absent in other populations. The crude MAF of rs3729712 from all patients with HCM in our study (0.055) was significantly higher than the upper limit of MAF (0.016) in one of the subpopulations of East Asians (P=1.44×10–9), which further validates the association signal.This study identified an East Asian–specific common variant TNNI3 rs3729712 associated with HCM. It reveals the existence of non-Mendelian inheritance of HCM and provides important insights into the complexity and ethnic differences of HCM genetic architecture.AcknowledgmentsThe authors thank the patients and their families for participation and the staff members for data collection, sample handling, and genotyping.Sources of FundingThis work was supported by grants from the Chinese Academy of Medical Sciences Innovation Fund for Medical Sciences (CAMS-I2M, 2016-I2M-1-015) and the National Natural Science Foundation of China (81870286 and 81470380).DisclosuresNone.Footnotes*Drs Wu, L. Liu, and Zhou contributed equally.https://www.ahajournals.org/journal/circThis manuscript was sent to Ju Chen, PhD, Guest Editor, for review by expert referees, editorial decision, and final disposition.Jizheng Wang, PhD, State Key Laboratory of Cardiovascular Disease, Cardiomyopathy Ward, Fuwai Hospital, National Center for Cardiovascular Disease, 167, Beilishilu, Xicheng District, 100037 Beijing, China; Email [email protected]comLei Song, MD, PhD, Cardiomyopathy Ward, Fuwai Hospital, National Center for Cardiovascular Disease, 167, Beilishilu, Xicheng District, 100037 Beijing, China; Email [email protected]comChao Xing, PhD, McDermott Center for Human Growth and Development, UT Southwestern Medical Center, 5323 Harry Hines Blvd, Dallas, TX 75390-8591. Email chao.[email protected]eduReferences1. Maron BJ.Clinical course and management of hypertrophic cardiomyopathy.N Engl J Med. 2018; 379:655–668. doi: 10.1056/NEJMra1710575CrossrefMedlineGoogle Scholar2. Walsh R, Buchan R, Wilk A, John S, Felkin LE, Thomson KL, Chiaw TH, Loong CCW, Pua CJ, Raphael Cet al.Defining the genetic architecture of hypertrophic cardiomyopathy: re-evaluating the role of non-sarcomeric genes.Eur Heart J. 2017; 38:3461–3468. doi: 10.1093/eurheartj/ehw603MedlineGoogle Scholar3. Maron BJ, Maron MS, Maron BA, Loscalzo J.Moving beyond the sarcomere to explain heterogeneity in hypertrophic cardiomyopathy: JACC review topic of the week.J Am Coll Cardiol. 2019; 73:1978–1986. doi: 10.1016/j.jacc.2019.01.061CrossrefMedlineGoogle Scholar4. Wang J, Wang Y, Zou Y, Sun K, Wang Z, Ding H, Yuan J, Wei W, Hou Q, Wang Het al.Malignant effects of multiple rare variants in sarcomere genes on the prognosis of patients with hypertrophic cardiomyopathy.Eur J Heart Fail. 2014; 16:950–957. doi: 10.1002/ejhf.144CrossrefMedlineGoogle Scholar5. Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, Grody WW, Hegde M, Lyon E, Spector Eet al.; ACMG Laboratory Quality Assurance Committee. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology.Genet Med. 2015; 17:405–424. doi: 10.1038/gim.2015.30CrossrefMedlineGoogle Scholar Previous Back to top Next FiguresReferencesRelatedDetailsCited ByWu G, Liu J, Liu M, Huang Q, Ruan J, Zhang C, Wang D, Sun X, Jiang W, Kang L, Wang J and Song L (2021) Truncating Variants in OBSCN Gene Associated With Disease-Onset and Outcomes of Hypertrophic Cardiomyopathy, Circulation: Genomic and Precision Medicine, 14:5, Online publication date: 1-Oct-2021. November 24, 2020Vol 142, Issue 21Article InformationMetrics Download: 1,026 © 2020 American Heart Association, Inc.https://doi.org/10.1161/CIRCULATIONAHA.120.050384PMID: 33078954 Originally publishedOctober 20, 2020 Keywordscardiomyopathy, hypertrophichypertrophygenetic testingAsiansPDF download SubjectsPrecision Medicine
What problem does this paper attempt to address?
-
The Novel Mitochondrial 16S Rrna 2336T>C Mutation is Associated with Hypertrophic Cardiomyopathy
Zhong Liu,Yanrui Song,Dan Li,Xiangyu He,Shishi Li,Bifeng Wu,Wei Wang,Shulian Gu,Xiaoyu Zhu,Xuexiang Wang,Qiyin Zhou,Yu Dai,Qingfeng Yan
DOI: https://doi.org/10.1136/jmedgenet-2013-101818
2013-01-01
Journal of Medical Genetics
Abstract:Background Hypertrophic cardiomyopathy (HCM) is a primary disorder characterised by asymmetric thickening of septum and left ventricular wall, with a prevalence of 0.2% in the general population.Objective To describe a novel mitochondrial DNA mutation and its association with the pathogenesis of HCM.Methods and results All maternal members of a Chinese family with maternally transmitted HCM exhibited variable severity and age at onset, and were implanted permanent pacemakers due to complete atrioventricular block (AVB). Nuclear gene screening (MYH7, MYBPC3, TNNT2 and TNNI3) was performed, and no potential pathogenic mutation was identified. Mitochondrial DNA sequencing analysis identified a novel homoplasmic 16S rRNA 2336T>C mutation. This mutation was exclusively present in maternal members and absent in non-maternal members. Conservation index by comparison to 16 other vertebrates was 94.1%. This mutation disturbs the 2336U-A2438 base pair in the stem-loop structure of 16S rRNA domain III, which is involved in the assembly of mitochondrial ribosome. Oxygen consumption rate of the lymphoblastoid cells carrying 2336T>C mutation had decreased by 37% compared with controls. A reduction in mitochondrial ATP synthesis and an increase in reactive oxidative species production were also observed. Electron microscopic analysis indicated elongated mitochondria and abnormal mitochondrial cristae shape in mutant cells.Conclusions It is suggested that the 2336T>C mutation is one of pathogenic mutations of HCM. This is the first report of mitochondrial 16S rRNA 2336T>C mutation and an association with maternally inherited HCM combined with AVB. Our findings provide a new insight into the pathogenesis of HCM.
-
Characteristics of the beta myosin heavy chain gene Ala26Val mutation in a Chinese family with hypertrophic cardiomyopathy.
Sheng-Xiang Liu,Shen-Jiang Hu,Jian Sun,Jing Wang,Xi-Tian Wang,Yan Jiang,Jing Cai
DOI: https://doi.org/10.1016/j.ejim.2005.02.008
IF: 7.749
2005-01-01
European Journal of Internal Medicine
Abstract:Genotype-phenotype studies have suggested that some mutations of genes encoding various components of the cardiac sarcomere cause hypertrophic cardiomyopathy (HCM) and are associated with the prognosis of patients with HCM. The aims of this study were to investigate the gene mutations of exons in the cardiac beta myosin heavy chain (MYH7) gene, the troponin T (TNNT2) gene, and the brain natriuretic peptide (BNP) gene, as well as to assess the effect of these mutations on the clinical features of Chinese patients with HCM.Five unrelated Chinese families with HCM were studied. Exons 3 and 18 in the MYH7 gene, exon 9 in the TNNT2 gene, and all three exons in the BNP gene were screened with the polymerase chain reaction (PCR) for genomic DNA amplification. Further study included purification of PCR products and direct sequencing of PCR fragments by fluorescent end labeling.A C-to-T transition in codon 26 of exon 3 in the MYH7 gene was found in one family (including four patients and five carriers), resulting in an amino acid substitution of valine (Val) for alanine (Ala). The Ala26Val mutation was of incomplete dominance (penetrance 44%). This mutation was not seen in the other four families or in the control group. Moreover, the association between the gene mutations of exon 18 in MYH7, of exon 9 of TNNT2, and of all three exons in BNP and HCM was not found in the populations we studied.The missense mutation Ala26Val found in this one Chinese family was associated with a mild phenotype of HCM. The genetic and phenotypic heterogeneity of HCM exists in the Chinese population. It suggests that genetic and environmental factors may be involved in the pathogenesis of HCM.
-
Inhibition of HSC70 Alleviates Hypertrophic Cardiomyopathy Pathology in Human Induced Pluripotent Stem Cell‐derived Cardiomyocytes with a MYBPC3 Mutation
Hangyuan Qiu,Yaxun Sun,Ziwei Pan,Jingjun Zhou,Hongkun Wang,Xiaochen Wang,Dongsheng Cai,Guosheng Fu,Tingyu Gong,Chenyang Jiang,Ping Liang
DOI: https://doi.org/10.1002/ctm2.647
IF: 8.554
2021-01-01
Clinical and Translational Medicine
Abstract:Dear Editor, We performed a comprehensive study to assess the pathogenicity of a cardiac myosin binding protein C3 (MYBPC3) variant (L460fs) and to pinpoint underlying molecular mechanisms by utilizing human-induced pluripotent stem cell-derived cardiomyocyte (iPSC-CM) model. L460fs iPSC-CMs exhibited a variety of deleterious phenotypes in response to angiotensin II (Ang II), including reducedMYBPC3 expression, hypertrophy, arrhythmia and elevated diastolic intracellular Ca2+ [Ca]i. Mechanistically, heat shock protein family A (HSP70) member 8 (HSC70) accelerated MYBPC3 degradation via lysosomal pathway under Ang II stress. The reduced MYBPC3binding ryanodine receptor 2 (RYR2) caused by insufficiency of MYBPC3 protein may give rise to excessive free destabilized RYR2, which in turn promoted RYR2mediated Ca2+ leak. The resultant elevated Ca2+ loading may trigger the development of both hypertrophy and arrhythmogenesis, particularly under stress conditions.1 Hypertrophic cardiomyopathy (HCM), featured by asymmetric ventricular hypertrophy, arrhythmias and sudden cardiac death (SCD), is the most common form of inherited cardiac disease.2,3 To note, HCM has been repeatedly regarded as a major cause of SCD in young people.4 MYBPC3, which encodes cardiac myosin-binding protein C, is the most frequent HCM-associated gene, accounting for more than 50% of the HCM patients.5 However, the exact mechanism of MYBPC3-related HCM remains to be resolved.6,7 In this study, a MYBPC3 variant (c.1377delC; p.L460fs) was identified in four-unrelated individuals who developed HCM in middle age (Figure 1A,B). The echocardiography and cardiac magnetic resonance imaging exhibited normal ventricular function, severe interventricular septum hypertrophy but without left ventricular outflow tract obstruction (Figure 1C, Figure S1A-D and Table S1). With treatment of β blockers or Ca2+ channel blockers,
-
[Advances in the Molecular Pathogenesis of Hypertrophic Cardiomyopathy].
Yan-Rui Song,Zhong Liu,Shu-Lian Gu,Li-Juan Qian,Qing-Feng Yan
DOI: https://doi.org/10.3724/sp.j.1005.2011.00549
2011-01-01
Abstract:Hypertrophic Cardiomyopathy (HCM) is a primary cardiac disorder characterized by asymmetric thickening of the septum and left ventricular wall. HCM affects 1 in 500 individuals in the general population, and it is the most common cause of sudden death in the young and athletes. The clinic phenotype of HCM is highly variable with respect to age at onset, degree of symptoms, and risk of sudden death. HCM is usually inherited as a Mendelian autosomal dominant trait. To date, over 900 mutations have been reported in HCM, which were mainly located in 13 genes encoding cardiac sarcomere protein, e.g., MYH7, MYBPC3, and TnT. In addition, more and more mitochondrial DNA mutations were reported to be associated with the pathogenesis of HCM. Based on the description of the clinical phenotype and morphological characteristics, this review focuses on the research in the molecular pathogenic mechanism of HCM and its recent advances.
-
Pgpm_a_314880 823..837
Zetao Ma,Xizhi Wang,Qingbo Lv,Yingchao Gong,Minghong Xia,Lenan Zhuang,Xue Lu,Ying Yang,Wenbin Zhang,Guosheng Fu,Yang Ye,Dongwu Lai
2021-01-01
Abstract:*These authors contributed equally to this work Background: Considered as one of the major reasons of sudden cardiac death, hypertrophic cardiomyopathy (HCM) is a common inherited cardiovascular disease. However, effective treatment for HCM is still lacking. Identification of hub gene may be a powerful tool for discovering potential therapeutic targets and candidate biomarkers. Methods: We analysed three gene expression datasets for HCM from the Gene Expression Omnibus. Two of them were merged by “sva” package. The merged dataset was used for analysis while the other dataset was used for validation. Following this, a weighted gene coexpression network analysis (WGCNA) was performed, and the key module most related to HCM was identified. Based on the intramodular connectivity, we identified the potential hub genes. Then, a receiver operating characteristic curve analysis was performed to verify the diagnostic values of hub genes. Finally, we validated changes of hub genes, for genetic transcription and protein expression levels, in datasets of HCM patients and myocardium of transverse aortic constriction (TAC) mice. Results: In the merged dataset, a total of 455 differentially expressed genes (DEGs) were identified from normal and hypertrophic myocardium. In WGCNA, the blue module was identified as the key module and the genes in this module showed a high positive correlation with HCM. Functional enrichment analysis of DEGs and key module revealed that the extracellular matrix, fibrosis, and neurohormone pathways played important roles in HCM. FRZB, COL14A1, CRISPLD1, LUM, and sFRP4 were identified as hub genes in the key module. These genes showed a good predictive value for HCM and were significantly up-regulated in HCM patients and TAC mice. We also found protein expression of LUM and sFRP4 increased in myocardium of TAC mice. Conclusion: This study revealed that five hub genes are involved in the occurrence and development of HCM, and they are potentially to be used as therapeutic targets and biomarkers for HCM.
-
Identification of Underlying Hub Genes Associated with Hypertrophic Cardiomyopathy by Integrated Bioinformatics Analysis
Zetao Ma,Xizhi Wang,Qingbo Lv,Yingchao Gong,Minghong Xia,Lenan Zhuang,Xue Lu,Ying Yang,Wenbin Zhang,Guosheng Fu,Yang Ye,Dongwu Lai
DOI: https://doi.org/10.2147/PGPM.S314880
2021-01-01
Abstract:Background: Considered as one of the major reasons of sudden cardiac death, hypertrophic cardiomyopathy (HCM) is a common inherited cardiovascular disease. However, effective treatment for HCM is still lacking. Identification of hub gene may be a powerful tool for discovering potential therapeutic targets and candidate biomarkers. Methods: We analysed three gene expression datasets for HCM from the Gene Expression Omnibus. Two of them were merged by "sva" package. The merged dataset was used for analysis while the other dataset was used for validation. Following this, a weighted gene coexpression network analysis (WGCNA) was performed, and the key module most related to HCM was identified. Based on the intramodular connectivity, we identified the potential hub genes. Then, a receiver operating characteristic curve analysis was performed to verify the diagnostic values of hub genes. Finally, we validated changes of hub genes, for genetic transcription and protein expression levels, in datasets of HCM patients and myocardium of transverse aortic constriction (TAC) mice. Results: In the merged dataset, a total of 455 differentially expressed genes (DEGs) were identified from normal and hypertrophic myocardium. In WGCNA, the blue module was identified as the key module and the genes in this module showed a high positive correlation with HCM. Functional enrichment analysis of DEGs and key module revealed that the extra cellular matrix, fibrosis, and neurohormone pathways played important roles in HCM. FRZB, COL14A1, CRISPLD1, LUM, and sFRP4 were identified as hub genes in the key module. These genes showed a good predictive value for HCM and were significantly up-regulated in HCM patients and TAC mice. We also found protein expression of LUM and sFRP4 increased in myocardium of TAC mice. Conclusion: This study revealed that five hub genes are involved in the occurrence and development of HCM, and they are potentially to be used as therapeutic targets and biomarkers for HCM.
-
Unveiling Immune Infiltration Characterizing Genes in Hypertrophic Cardiomyopathy Through Transcriptomics and Bioinformatics
DOI: https://doi.org/10.2147/jir.s454446
IF: 4.5
2024-05-17
Journal of Inflammation Research
Abstract:Jianmin Gong, 1, 2, &ast Bo Shi, 1, 3, &ast Ping Yang, 1 Adeel Khan, 4 Tao Xiong, 2 Zhiyang Li 1 1 Department of Clinical Laboratory, Nanjing Drum Tower Hospital, Nanjing Drum Tower Hospital Clinical College of Nanjing Medical University, Nanjing, 210000, People's Republic of China; 2 College of Life Science, Yangtze University, Jingzhou, 434025, People's Republic of China; 3 Department of Clinical Laboratory, Nanjing Jiangning Hospital of Chinese Medicine (CM), Nanjing, 211100, People's Republic of China; 4 Department of Biotechnology, University of Science and Technology Bannu, Bannu, 28100, Islamic Republic of Pakistan &astThese authors contributed equally to this work Correspondence: Tao Xiong, College of Life Science, Yangtze University, Jingzhou, 434025, People's Republic of China, Tel +8613872387410, Email Zhiyang Li, Department of Clinical Laboratory, Nanjing Drum Tower Hospital, Nanjing Drum Tower Hospital Clinical College of Nanjing Medical University, Nanjing, 210008, People's Republic of China, Tel +8618951703765, Email Background: Hypertrophic cardiomyopathy (HCM) is a dominantly inherited disease associated with sudden immune cell associations that remain unclear. The aim of this study was to comprehensively screen candidate markers associated with HCM and immune cells and explore potential pathogenic pathways. Methods: First, download the GSE32453 dataset to identify differentially expressed genes (DEGs) and perform Gene Ontology and pathway enrichment analysis using DAVID and GSEA. Next, construct protein-protein interaction (PPI) networks using String and Cytoscape to identify hub genes. Afterward, use CIBERSORT to determine the proportion of immune cells attributed to key genes in HCM and conduct ROC analysis based on the external dataset GSE36961 to evaluate their diagnostic value. Finally, validate the expression of key genes in the hypertrophic cardiomyocyte model through qRT-PCR using data from the HPA database. Results: Comprehensive analysis revealed that there were 254 upregulated genes and 181 downregulated genes in HCM. The enrichment study underscored pathways of inflammatory signaling, including MAPK and PI3K-Akt pathways. Pathways abundant in genes associated with HCM encompassed myocardial contraction and NADH dehydrogenase activity. Additionally, the analysis of immune infiltration revealed a notable increase in macrophages, NK cells, and monocytes in the HCM group, showing statistically significant variances in CD4 memory resting T cell infiltration when compared to the healthy control group. Within the validation dataset GSE36961, the Area Under the Curve (AUC) scores for eight crucial genes (FOS, CD86, CD68, BDNF, PIK3R1, PLEK, RAC2, CCL2) each exceeded 0.8. The HPA database revealed the positioning traits and paths of these eight crucial genes in smooth muscle cells, myocardial cells, and fibroblasts. The outcomes of the qRT-PCR were aligned with the sequencing findings. Conclusion: Bioinformatics analysis unveiled pivotal genes, pathways, and immune involvement, illuminating the molecular underpinnings of HCM. These findings suggest promising therapeutic targets for clinical applications. Keywords: hypertrophic cardiomyopathy, bioinformatic, immune cells infiltration, biomarker Hypertrophic cardiomyopathy (HCM) is a heterogenic genetic disease most commonly caused by sarcomeric mutations that lead to left ventricular hypertrophy, fibrosis, hypercontractility and reduced compliance. 1 The intricate nature of hypertrophic cardiomyopathy involves a combination of diastolic dysfunction, myocardial ischaemia, and outflow tract obstruction and arrhythmias caused by the displacement of the mitral valve in the front. From a clinical standpoint, the symptomatology exhibits a wide range, encompassing no discernible symptoms as well as palpitations, dyspnoea, diminished exercise capacity, chest discomfort, syncope, and even abrupt demise. 2 Epidemiological studies indicate that at least 1 in every 500 individuals is affected by hypertrophic cardiomyopathy, while 1 in every 200 individuals is either affected by it or has a genetic predisposition. 3 Despite functional and genome-wide association studies (GWAS) suggesting an association between the FHOD3 gene and myocardial hypertrophy, no pathogenic variants directly related to hypertrophic cardiomyopathy have been identified. 4 While significant progress has been made in the diagnosis through the use of echocardiography, clinical diagnosis still faces several challenges, including the diversity of clinical manifestations, uncertainty in imaging exa -Abstract Truncated-
immunology
-
Identification of a LMNA (c.646c > T) Variant by Whole-Exome Sequencing in Combination with a Dilated Cardiomyopathy (DCM) Related Gene Filter in a Family with Familiar DCM
Liang Chen,Zhou Zhongyin,Hang Lu,Yan Xie,Gang Li,Jianfei Huang,Zhao Dong-sheng
DOI: https://doi.org/10.7555/jbr.32.20180003
2018-01-01
Abstract:Dilated cardiomyopathy (DCM) is characterized by the dilated heart chambers and reduced systolic function in the absence of specific aetiology [1] .Approximately one third of DCM cases are hereditary.In recent years, DCM concomitant with arrhythmias and sudden death resulting from gene mutation has been widely reported [2] .In the current study, we report the identification of a mutation within lamin A (LMNA) (p.R216C) in a Han Chinese family with similar cardiac manifestations by using whole-exome sequencing in combination with a related gene filter and co-segregation analysis.The study was approved by the local Ethics Committee of the First People ' s Hospital of Nantong Jiangsu.A family from Jiangsu Province in eastern China was investigated with 24 hours-Holter monitoring and transthoracic echocardiography and the pedigree was built using Microsoft Office [3] .The information of the family members is shown in Fig. 1 and Table 1.Ⅲ4 (the proband, male, 53 years old) was hospitalized due to recurrent dizziness and amaurosis in 2012.The electrocardiogram showed grade 3 atrioventricular block (AVB), and a pacemaker was implanted.Both Ⅱ5 (male, 71 years old) and Ⅱ11 (male, 63 years old) had heart enlargement and pacemaker implantation for grade 3 AVB, and suffered from atrial fibrillation (2
-
Novel Phenotype–genotype Correlations of Hypertrophic Cardiomyopathy Caused by Mutation in Α-Actin and Myosin-Binding Protein Genes in Three Unrelated Chinese Families
Qian-Li Yang,Yang-Yang Bian,Bo Wang,Lei Zuo,Meng-Yao Zhou,Hong Shao,Yan-Min Zhang,Li-Wen Liu
DOI: https://doi.org/10.1016/j.jjcc.2018.09.005
IF: 2.974
2019-01-01
Journal of Cardiology
Abstract:Background: The correlations between genotype and phenotype in hypertrophic cardiomyopathy (HCM) have not been established. Mutation of alpha-actin gene (ACTC1) is a rare cause of HCM. This study aimed to explore novel genotype-phenotype correlations in HCM patients with the variants in ACTC1 and myosin binding protein (MYBPC3) genes in three unrelated Chinese families. Methods: Clinical, electrocardiographic, and echocardiographic examinations were performed in three Han pedigrees. Exon and boarding intron analysis of 96 cardio-disease-related genes was performed using second-generation sequencing on three probands. The candidate variants were validated in 14 available family members and 300 unrelated healthy controls by bi-directional Sanger sequencing. The pathogenicity and conservation were calculated using MutationTaster, PolyPhen-2, SIFT, and Clustal X. Pathogenicity classification of the variants was based on American College of Medical Genetics and Genomics (ACMG) guidelines. Results: Nine members fulfilled diagnostic criteria for HCM with clinical characteristics, electrocardiographic, and echocardiographic findings. Two candidate variants in ACTC1 p.Asp26Asn (ACTC1-D26N) and MYBPC3 p.Arg215Cys (MYBPC3-R215C) were identified in patients. Only ACTC1-D26N strongly co-segregated with the HCM phenotype. Seven patients who harbored variant ACTC-D26N only were diagnosed with non-obstructive HCM, and four of these patients exhibited a triphasic left ventricular (LV) filling pattern. Two patients carrying both ACTC1-D26N and MYBPC3-R215C variants showed a higher LV outflow tract pressure gradient. Bioinformatics analysis revealed that the two variants were deleterious and highly conserved across species. According to ACMG guidelines, ACTC1-D26N is classified as a likely pathogenic mutation. The second variation MYBPC3-R215C may function as a genetic modifier, which remains uncertain here. Conclusions: Novel p.(Asp26Asn) mutation of ACTC1 was associated with HCM phenotype, and the penetrance is extremely high (similar to 81.8%) in adults. The second variation, MYBPC3-R215C may function as a genetic modifier, which remains uncertain here. (C) 2018 Japanese College of Cardiology. Published by Elsevier Ltd. All rights reserved.
-
Association of Angiotensinogen Gene M235T Variant with Hypertrophic Cardiomyopathy
Si-yu Cai,Yu-ping Shi,Feng Yu,Geng Xu
DOI: https://doi.org/10.3760/j.issn:1003-9406.2004.03.024
2004-01-01
Abstract:OBJECTIVE:To evaluate the influence of the angiotensinogen(AGT) gene M235T variant on the prevalence and severity of hypertrophic cardiomyopathy(HCM).METHODS:The authors conducted a case-control study on 152 subjects, including 72 HCM patients and 80 normal controls. Polymerase chain reaction(PCR) combined with restriction fragment length polymorphism(RFLP) was used to detect the M235T variant of AGT gene. Interventricular septum thickness, left ventricular posterior wall thickness and apical wall thickness were measured by means of M-mode echocardiography under two-dimensional guidance in the parasternal long-axis plane and apical two- and four-chamber views.RESULTS:(1) The genotype distributions of AGT gene in both groups were in agreement with Hardy-Weinberg equilibrium. (2) The genotype distributions of the M235T variant differed significantly in HCM patients and controls(chi-square=6.090 P<0.05). The frequencies of TT genotype and T235 allele in HCM patients were higher than did the patients in controls(TT genotype 0.63 vs 0.45 OR=2.037 95%CI 1.064-7.899 P<0.05 T235 allele 0.78 vs 0.64 OR=1.990 95%CI 1.197-3.308 P<0.01). (3)The patients with the TT genotype had significantly greater mean left ventricular maximal wall thickness than did the patients with the MM and MT genotypes [(19.1+/-4.8) mm vs(15.3+/-2.6)mm and(16.2+/-5.1)mm F=4.261 P<0.05].CONCLUSION:The variant M235T of the AGT gene is significantly associated with HCM in this population. The genotype TT or allele T might be a genetic risk factor for the development and extent of hypertrophy in HCM patients.
-
Echocardiographic Characterization of Hypertrophic Cardiomyopathy in Chinese Patients with Myosin-Binding Protein C3 Mutations.
Bei Zhao,Shouli Wang,Jinsong Chen,Yali Ji,Jing Wang,Xiaoli Tian,Guang Zhi
DOI: https://doi.org/10.3892/etm.2017.4089
IF: 2.7
2017-01-01
Experimental and Therapeutic Medicine
Abstract:Hypertrophic cardiomyopathy (HCM) is a common autosomal dominant cardiac disease, affecting 1 in 500 people. Myosin-binding protein C3 (MyBPC3) gene mutations are the most common genetic cause of HCM. However, the prevalence of the MyBPC3 gene mutation in Chinese patients with HCM, and their echocardiographic characteristics, remain unknown. In the present study, 48 Chinese patients with HCM were sequenced to identify the MyBPC3 gene and were characterized by their clinical features using 2-dimensional echocardiography and real-time 3-dimensional echocardiography. Nine MyBPC3 mutations were identified in seven unrelated patients out of 48 cases, which accounts for a 15% prevalence of MyBPC3 mutations in Chinese patients with HCM. Family members of the seven patients were further tested and divided into the following two groups based on HCM phenotype and MyBPC3 mutations: Positive genotype with left ventricular (LV) hypertrophy (LVH) (G+/LVH+, n=18); and positive genotype without LVH (G+/LVH-, n=23). These groups were compared with matched normal control subjects (n=30). G+/LVH+ patients showed significantly lower septal and lateral Tissue Doppler imaging (TDI)-derived systolic, early and late diastolic mitral annular velocities compared with the controls. In addition, diastolic dyssynchrony index (DDI) was markedly higher in the G+/LVH+ subjects. However, only septal Ea was significantly lower in G+/LVH- subjects in comparison with controls, with no significant difference in lateral Sa, Ea and Aa, and DDI. In conclusion, the patients in the present study demonstrated a 15% prevalence of MyBPC3 gene mutations in the Chinese HCM population. MyBPC3 gene mutations may cause regional LV hypertrophic remodeling first and further proceed to global hypertrophic remodeling and myocardial diastolic dysfunction.
-
[Mutation and Clinical Relevance in a Large Cohort of Unrelated Chinese Patients with Hypertrophic Cardiomyopathy].
Jie Liu,Wen‐ling Liu,Dayi Hu,Tiangang Zhu,Wen Liu,Ma Zhanfeng,Jie Yang,Wen-li Xie,Cuilan Li,Lei Li,Pan Guozhong
2015-01-01
Abstract:To explore the genetic basis and phenotypic correlation with disease severity in a large cohort of Chinese patients with hypertrophic cardiomyopathy (HCM).A total of 179 unrelated Chinese HCM patients admitted to our department from 2002 to 2011 were enrolled in this study. Direct gene sequencing of β-myosin heavy chain (MYH7), myosin binding protein-C ( MYBPC3), and cardiac troponin T (TNNT2) were performed and clinical data were obtained in these patients.A total of 34 mutations were identified in 40 patients (22.3%), 79.4% (27/34) mutations occurred only once and a possible hot spot, A26 in MYH7, was found. Distribution of mutations was 52.9% (18/34) (MYBPC3), 35.3% (12/34) ( MYH7) and 11.8% (4/34) (TNNT2) respectively. Double mutations were identified in 2.2% (4/179) patients. Genotype-positive patients were associated with an earlier symptom onset, severer left ventricular hypertrophy, a higher incidence of syncope, and were more likely to have positive family history of HCM or sudden cardiac death (SCD) , and were more likely to progress into heart failure (24.2% vs. 5.0%, P = 0.002) and at a higher risk of SCD (9.1% vs. 0, P = 0.009) during the 6.5-year follow-up. No statistical difference in any clinical parameters and outcomes was found between patients carrying MYBPC3 and MYH7 mutations. Double mutations were associated with malignant clinical progression in this cohort. Different phenotype severity could be seen in HCM patients with same genotype (e. g. MYH7-1736T, TNNT2-R92W).MYBPC3 is the most predominant gene mutation in this HCM cohort. The presence of a sarcomere mutation in patients with HCM is associated with poor clinical outcome, although no specific genes or mutations can exactly predict the severity of clinical phenotypes.
-
Next-generation sequencing identifies pathogenic and modifier mutations in a consanguineous Chinese family with hypertrophic cardiomyopathy
Xinlin Zhang,Jun Xie,Suhui Zhu,Yuhan Chen,Lian Wang,Biao Xu
DOI: https://doi.org/10.1097/MD.0000000000007010
Abstract:Hypertrophic cardiomyopathy (HCM) is a highly heterogeneous disease displaying considerable interfamilial and intrafamilial phenotypic variation, including disease severity, age of onset, and disease progression. This poorly understood variance raises the possibility of genetic modifier effects, particularly in MYBPC3-associated HCM.In a large consanguineous Chinese HCM family, we identified 8 members harboring the MYBPC3 c.3624delC (p.Lys1209Serfs) disease-causing mutation, but with very disparate phenotypes. Genotyping ruled out the modifying effect of previously described variants in renin-angiotensin-aldosterone system. Afterwards, we screened for modifying variants in all known causing genes and closely related genes for cardiomyopathy and channelopathy by performing targeted next-generation sequencing. For first time, we showed that a c.1598C>T (p.Ser533Leu) mutation in voltage-dependent l-type calcium channel subunit beta-2 (CACNB2) was present in all severely affected HCM patients, but not in those moderately affected or genotype-positive phenotype-negative patients. This CACNB2 p.Ser533Leu mutation is extremely conserved in evolution, and was not found in 550 healthy controls.Our results suggest that CACNB2 is a possible candidate genetic modifier of MYBPC3-associated familial HCM, but more genetic evidence and functional experiments are needed to confirm.
-
Mitochondrial Dysfunctions Contribute to Hypertrophic Cardiomyopathy in Patient Ipsc-Derived Cardiomyocytes with MT-RNR2 Mutation.
Shishi Li,Huaye Pan,Chao Tan,Yaping Sun,Yanrui Song,Xuan Zhang,Wei Yang,Xuexiang Wang,Dan Li,Yu Dai,Qiang Ma,Chenming Xu,Xufen Zhu,Lijun Kang,Yong Fu,Xuejun Xu,Jing Shu,Naiming Zhou,Feng Han,Dajiang Qin,Wendong Huang,Zhong Liu,Qingfeng Yan
DOI: https://doi.org/10.1016/j.stemcr.2018.01.013
2018-01-01
Stem Cell Reports
Abstract:Hypertrophic cardiomyopathy (HCM) is the most common cause of sudden cardiac death in young individuals. A potential role of mtDNA mutations in HCM is known. However, the underlying molecular mechanisms linking mtDNA mutations to HCM remain poorly understood due to lack of cell and animal models. Here, we generated induced pluripotent stem cell-derived cardiomyocytes (HCM-iPSC-CMs) from human patients in a maternally inherited HCM family who carry the m.2336T>C mutation in the mitochondrial 16S rRNA gene (MT-RNR2). The results showed that the m.2336T>C mutation resulted in mitochondrial dysfunctions and ultrastructure defects by decreasing the stability of 16S rRNA, which led to reduced levels of mitochondrial proteins. The ATP/ADP ratio and mitochondrial membrane potential were also reduced, thereby elevating the intracellular Ca2+ concentration, which was associated with numerous HCM-specific electrophysiological abnormalities. Our findings therefore provide an innovative insight into the pathogenesis of maternally inherited HCM.
-
Mechanisms of pathogenicity in the hypertrophic cardiomyopathy-associated TNNI3 c.235C > T variant
Lai Zhang,Fengzhi Ding,Zhongyuan Ren,Weili Cheng,He Dai,Qing Liang,Fanling Kong,Wenjing Xu,Minghui Wang,Yuqing Zhang,Qin Tao
DOI: https://doi.org/10.1016/j.ijcard.2024.132627
IF: 4.039
2024-11-10
International Journal of Cardiology
Abstract:Background Hypertrophic cardiomyopathy (HCM) is typically manifested as a hereditary disorder, with 30 %–60 % of cases linked to cardiac sarcomere gene mutations. Despite numerous identified TNNI3 mutations associated with HCM, their severity, prevalence, and disease progression vary. The link between TNNI3 variants and phenotypes remains largely unexplored. This study aims to elucidate the impact of the TNNI3 c.235C > T mutation on HCM through clinical research and cell experiments and to explore its mechanism in HCM development. Methods We screened an HCM family for pathogenic gene mutations using gene sequencing. The proband and family members were assessed through electrocardiography, echocardiography, and cardiac MRI, and a pedigree map was created for disease prediction analysis. Mutant plasmids were constructed with the TNNI3 c.235C > T mutation and transfected into the AC16 human cardiomyocyte cell line to investigate the mutation's effects. Results The TNNI3 c.235C > T mutation was identified as the disease-causing variant in the family. This mutation led to the upregulation of hypertrophy-associated genes ANP, BNP , and MYH7 , increased cardiomyocyte size, and activation of the ERK signaling pathway. Further investigations revealed that the TNNI3 c.235C > T mutation impaired mitochondrial function, disrupted cardiomyocyte metabolism, and increased cellular autophagy and apoptosis. Conclusions The TNNI3 c.235C > T gene mutation may be a pathogenic factor for HCM, showing heterogeneous features and clinical phenotypes. This mutation induces myocardial hypertrophy, activates the ERK signaling pathway, and exacerbates mitochondrial dysfunction, apoptosis, and autophagy in cardiomyocytes. These findings provide insights into the mechanism of HCM caused by gene mutations and may inform HCM treatment strategies.
cardiac & cardiovascular systems
-
A pathogenic nonsense mutation (c.1522C>T) of the MYBPC3 gene is implicated with hypertrophic cardiomyopathy
Erru Ni,Tao Wang,Xuan Zhang,Huabin Xie
DOI: https://doi.org/10.1002/ehf2.14424
Abstract:Hypertrophic cardiomyopathy (HCM), a genetically and clinically heterogeneous cardiomyopathy, is commonly caused by mutations in the MYBPC3 gene or other various sarcomeric genes. HCM patients carrying sarcomeric gene mutations may experience an asymptomatic period at early stage but still possess an escalating risk of developing adverse cardiac events including sudden cardiac death. It is crucial to determine the phenotypic and pathogenic effects of mutations in sarcomeric genes. In this study, a 65-year-old male was admitted with a history of chest pain, dyspnoea, and syncope and with a family history of HCM and sudden cardiac death. On admission, electrocardiogram indicated atrial fibrillation and myocardial infarction. Transthoracic echocardiography revealed left ventricular concentric hypertrophy and systolic dysfunction (48%), which were ascertained by cardiovascular magnetic resonance. With late gadolinium-enhancement imaging, cardiovascular magnetic resonance found myocardial fibrosis on left ventricular wall. The exercise stress echocardiography test showed non-obstructive myocardial changes. Whole-exome sequencing analysis identified a MYBPC3 gene heterozygous nonsense variant (c.1522C>T) in the patient and one of his healthy grandnieces (18-year-old). The patient was diagnosed with non-obstructive HCM, heart failure, atrial fibrillation, and so on. Medications, ICD implantation, and catheter ablation were chosen to maintain heart function. Our study provides the clinical evidence regarding the HCM pathogenicity of MYBPC3 c.1522C>T variant and highlights the significance of family genetic testing in the diagnosis and management of HCM.
-
The Involvement of ALPK3 in Hypertrophic Cardiomyopathy in East Asia
Jiaqi Dai,Ke Li,Man Huang,Yang Sun,Hao Liu,Zongzhe Li,Peng Chen,Hong Wang,Dongyang Wu,Yanghui Chen,Lei Xiao,Haoran Wei,Rui Li,Liyuan Peng,Ting Yu,Yan Wang,Dao Wen Wang
DOI: https://doi.org/10.3389/fmed.2022.915649
IF: 3.9
2022-06-15
Frontiers in Medicine
Abstract:Objective ALPK3 is associated with a recessive form of pediatric cardiomyopathy accompanied by musculoskeletal and craniofacial abnormalities. Heterozygous truncating variants in this gene ( ALPK3 tv) have recently been confirmed as a cause of autosomal dominant hypertrophic cardiomyopathy (HCM). Whether ALPK3 is also implicated in HCM in East Asia and the effect of missense variants in ALPK3 on HCM remains unresolved. Methods We compared the frequency of rare deleterious variants in ALPK3 in a study cohort comprised of 793 HCM cases of East Asian descent to that in the controls subset of Genome Aggregation Database (gnomAD). Gene burden test was used to assess this association. The involvement of these variants in HCM was further validated by independent cohort. The clinical characteristics and prognoses of these carriers were compared with sarcomere-positive and negative patients. Results Rare deleterious variants in ALPK3 were significantly enriched in HCM compared with gnomAD controls (truncating: 4/793 vs. 4/4523, P = 0.02; missense: 25/793 vs. 46/4523, P = 2.56e-5). Replication in an independent cohort provided more supporting evidence. Further comparisons revealed that ALPK3 carriers displayed more severe hypertrophy in interventricular septum (IVS) and apex, as well as greater maximal left ventricular wall thickness, relative to sarcomere negatives. Conclusion Heterozygous rare variants in ALPK3 , both missense and truncating variants, are associated with HCM in East Asians.
medicine, general & internal
-
Genetic Dissection of Hypertrophic Cardiomyopathy with Myocardial RNA-Seq
Jun Gao,John Collyer,Maochun Wang,Fengping Sun,Fuyi Xu
DOI: https://doi.org/10.3390/ijms21093040
IF: 5.6
2020-04-25
International Journal of Molecular Sciences
Abstract:Hypertrophic cardiomyopathy (HCM) is an inherited disorder of the myocardium, and pathogenic mutations in the sarcomere genes myosin heavy chain 7 (MYH7) and myosin-binding protein C (MYBPC3) explain 60%–70% of observed clinical cases. The heterogeneity of phenotypes observed in HCM patients, however, suggests that novel causative genes or genetic modifiers likely exist. Here, we systemically evaluated RNA-seq data from 28 HCM patients and 9 healthy controls with pathogenic variant identification, differential expression analysis, and gene co-expression and protein–protein interaction network analyses. We identified 43 potential pathogenic variants in 19 genes in 24 HCM patients. Genes with more than one variant included the following: MYBPC3, TTN, MYH7, PSEN2, and LDB3. A total of 2538 protein-coding genes, six microRNAs (miRNAs), and 1617 long noncoding RNAs (lncRNAs) were identified differentially expressed between the groups, including several well-characterized cardiomyopathy-related genes (ANKRD1, FHL2, TGFB3, miR-30d, and miR-154). Gene enrichment analysis revealed that those genes are significantly involved in heart development and physiology. Furthermore, we highlighted four subnetworks: mtDNA-subnetwork, DSP-subnetwork, MYH7-subnetwork, and MYBPC3-subnetwork, which could play significant roles in the progression of HCM. Our findings further illustrate that HCM is a complex disease, which results from mutations in multiple protein-coding genes, modulation by non-coding RNAs and perturbations in gene networks.
biochemistry & molecular biology,chemistry, multidisciplinary
-
[A Frame Shift Mutation, Arg346fs Mutation, is Identified in Cardiac Myosin-Binding Protein C Gene in a Chinese Family with Hypertrophic Cardiomyopathy].
Wen-li Xie,Wen-ling Liu,Da-yi Hu,Wei Cui,Tian-gang Zhu,Cui-lan Li,Yi-hong Sun,Lei Li,Hong Bian
DOI: https://doi.org/10.3760/j:issn:0376-2491.2005.14.009
2005-01-01
Abstract:OBJECTIVE To explore the disease-causing gene mutation in Chinese with hypertrophic cardiomyopathy (HCM). METHODS The peripheral venous blood samples were collected from 5 HCM families without consanguinity, including 5 probands, 2 males and 3 females, 28 sporadic HCM patients, 18 males and 10 females, and 80 healthy controls. The exons in the functional regions of cardiac myosin-binding protein C (MYBPC3) were amplified with PCR and the amplified products were sequenced. RESULTS A frame shift mutation-Arg346fs mutation in exon 13, the first mutation identified in Chinese-was discovered in one family with HCM. However, the members of the same HCM family with the Arg346fs mutation showed differences in phenotype and prognosis. CONCLUSION Cardiac myosin-binding protein C (MYBPC3) may be one of the main disease-causing genes. The heterogeneity of phenotype suggests that multiple factors may be involved in the pathogenesis.
-
The Cumulative Effects of the MYH7-V878A and CACNA1C-A1594V Mutations in a Chinese Family with Hypertrophic Cardiomyopathy
Guo Ruiqi,Bo Wang,Jing Wang,Fan Yang,Lei Zuo,Ying Liu,Hong Shao,Ju Yan,Lifeng Wang,Yanmin Zhang,Liwen Liu
DOI: https://doi.org/10.1159/000478900
2017-01-01
The Cardiology
Abstract:Aims: We investigated the pathogenesis of MYH7-V878A and CACNA1C-A1594V mutations in a Chinese family with hypertrophic cardiomyopathy. Methods: Clinical, electrocardiographic (ECG), echocardiographic, and cardiac magnetic resonance (CMR) examinations of members of a Chinese family were followed by exon and boarding intron analyses of 96 genes in the proband using second-generation sequencing. We confirmed the mutations by bidirectional Sanger sequencing in the members and in 300 healthy controls. Results: We detected MYH7-V878A and CACNA1C-A1594V mutations in this family. The members with both mutations showed inverted T-waves and ST-segment depression in ECG recordings, severe left ventricular (LV) hypertrophy in echocardiography, and myocardial fibrosis in CMR; subject II-11 did not show late gadolinium enhancement. Among those with only the MYH7-V878A mutation, subject III-7 showed abnormal ECG recordings, asymmetric septal hypertrophy, and myocardial fibrosis, and subjects II-13 and III-15 showed some abnormal repolarization, borderline LV wall thickness, and normal CMR findings. Those with only the CACNA1C-A1594V mutation showed nearly normal readings in all examinations. The members with both mutations displayed more severe LV hypertrophy and elevated LV filling pressure than those with 1 or no mutation (p < 0.05). Conclusion: Our results suggest that the pathogenesis of MYH7-V878A and CACNA1C-A1594V mutations may have a cumulative effect.